Results 91 to 100 of about 48,983 (212)

Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development

International Journal of Dermatology, EarlyView.
ABSTRACT Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease, with a rising incidence in the elderly. BP is associated with multiple triggering factors, including drug exposure. However, evidence in this respect is limited, and the underlying immune mechanisms remain unknown.
Belen de Nicolas‐Ruanes, Carlos Fernandez‐Lozano, Patricia Gutierrez‐Canales, Asuncion Ballester‐Martinez, Natalia Rodriguez‐Otero, Javier Martinez‐Botas, Belén de la Hoz Caballer, Ana Andres‐Martin, Emilio Solano‐Solares, Maria Esther Gomez‐Salazar Lopez‐Silanes, Laura Gisella Diaz‐Montalvo, Diana M. Arrebola, Vivian Lizeth Stewart‐Delcid, Emilio Garcia‐Mouronte, Carlos Azcarraga‐Llobet, Emilio Berna‐Rico, Sonia Ortega‐Sanchez, Montserrat Fernandez‐Guarino   +17 more
wiley   +1 more source

Medicinal cannabis: is current use clinically justified?

Internal Medicine Journal, EarlyView.
Abstract Cannabis products are increasingly perceived and advertised as natural and safe treatments for a variety of conditions, including chronic non‐cancer pain (CNCP). The number of prescriptions for medicinal cannabis (MC) currently averages >80 000 per month for >1 million Australians. Although over 800 different cannabis products are available to
Russ J. Scott, Ian A. Scott
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This large‐scale, propensity‐matched retrospective cohort study provides evidence that dupilumab treatment during pregnancy is not associated with an elevated risk of maternal adverse pregnancy outcomes (APOs). By utilizing real‐world data, it contributes critical insights into dupilumab's safety profile in pregnant women, addressing a crucial gap in ...
Sophie L. Preuß, Katja Bieber, Artem Vorobyev, Andreas Recke, Eva Lotta Moderegger, Henner Zirpel, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin, Ralf J. Ludwig   +9 more
wiley   +1 more source

Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Psoriasis affects 2–3% of the population, with numerous biologic options complicating treatment selection. This real‐world study found IL‐23p19 inhibitors offer the longest‐lasting effectiveness and safety. Psoriatic arthritis reduced ustekinumab survival, and prior biologic use impacted persistence, especially for IL‐17 inhibitors.
Leila Motedayen Aval, Zenas Z. N. Yiu, Oras A. Alabas, Christopher E. M. Griffiths, Nick J. Reynolds, Philip J. Hampton, Catherine H. Smith, Richard B. Warren, BADBIR Study Group   +8 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs

Journal of Veterinary Pharmacology and Therapeutics, Volume 48, Issue 3, Page 135-145, May 2025.
ABSTRACT Apoquel(oclacitinib maleate) as a film‐coated tablet, a selective Janus kinase (JAK)1 inhibitor, was approved by the United States Food and Drug Administration (FDA) in 2013 for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Steven M. Nederveld, Matthew J. Krautmann, John Mitchell   +2 more
wiley   +1 more source

Oral Adverse Effects of Antipsychotic Medications: A Case/Noncase Analysis of EudraVigilance Data

Oral Diseases, EarlyView.
ABSTRACT Objective Neuropsychiatric disorders are associated with poor oral health, with antipsychotics as potential contributors. This study aimed to analyse the oral adverse effects of antipsychotics using the EudraVigilance database. Methods A case/noncase analysis was conducted to calculate reporting odds ratios (ROR) and assess the ...
Leire Urien, Unax Lertxundi, Montserrat Garcia, Carmelo Aguirre, Nerea Jauregizar, Teresa Morera‐Herreras   +5 more
wiley   +1 more source

Risk of Cardiovascular Disease and Cancer in Patients Initiating JAK Versus IL‐4/‐13 Inhibitors for Atopic Dermatitis

International Journal of Dermatology, EarlyView.
Sizheng Steven Zhao, Gema Hernandez, Uazman Alam   +2 more
wiley   +1 more source

An mHealth app technology to strengthen adverse event management of multi‐drug‐resistant tuberculosis in Vietnam: Protocol for a process evaluation of the V‐SMART trial

Tropical Medicine &International Health, Volume 30, Issue 4, Page 273-282, April 2025.
Abstract Background Drug‐related adverse events cause poorer treatment outcomes amongst people with multi‐drug‐resistant tuberculosis, exacerbating a major global public health problem. The Harnessing new mHealth technologies to Strengthen the Management of Multi‐Drug‐Resistant Tuberculosis in Vietnam (V‐SMART) trial tests whether a mobile health ...
Binh Hoa Nguyen, Tho T. H. Dang, Duy Trinh Hoang, Thu Thuong Do, Luong Van Dinh, Viet Nhung Nguyen, Dinh Hoa Vu, Dorothy Drabarek, Tram N. B. Nguyen, Dang Vu, Thu Anh Nguyen, Guy B. Marks, Joel Negin, Greg J. Fox, Sarah Bernays, H. Manisha Yapa   +15 more
wiley   +1 more source